Adalimumab as a cause of kidney injury in patients with Crohn's disease

被引：0
|
作者：
Skoczynski, Krzysztof [1 ,2 ]
Koziej, Jan [1 ,2 ]
Szymanska, Sylwia [3 ]
Obrycki, Lukasz [1 ]
Grenda, Ryszard [1 ]
Litwin, Mieczyslaw [1 ,4 ]
机构：
[1] Childrens Mem Hlth Inst, Dept Nephrol Kidney Transplantat & Hypertens, Warsaw, Poland
[2] Cardinal Stefan Wyszynski Univ, Fac Med, Coll Med, Warsaw, Poland
[3] Childrens Mem Hlth Inst, Dept Pathol, Warsaw, Poland
[4] Ctr Continuing Med Educ, Chair Pediat Nephrol, Warsaw, Poland
来源：
PEDIATRIC NEPHROLOGY | 2024年 / 39卷 / 08期
关键词：
Kidney injury; Adalimumab; Drug reaction; Crohn's disease;
D O I：
10.1007/s00467-024-06338-0
中图分类号：
R72 [儿科学];
学科分类号：
100202 ;
摘要：
IntroductionAdalimumab (ADM) is a recombinant human monoclonal antibody (anti-TNF alpha) used to treat inflammatory bowel diseases. It can cause kidney injury (KI).Case diagnosis/treatmentWe describe two pediatric patients with Crohn's disease (CD) in whom ADM therapy was associated with kidney injury (KI). The drug was discontinued in both cases. For the first patient, changes were irreversible despite intensive glucocorticosteroid (GCS) therapy. For the second patient, discontinuation of ADM led to an improvement in kidney function.ConclusionsDue to the risk of KI in patients undergoing ADM therapy, careful assessment of kidney function and early specialist referral are required. Timely withdrawal of ADM can significantly reduce kidney damage, but in some cases, the kidney damage can be irreversible.
引用
收藏
页码：2359 / 2361
页数：3
相关论文
共 50 条
  • [31] Serum Adalimumab Concentration and Clinical Remission in Patients with Crohn's Disease
    Chiu, Yi-Lin
    Rubin, David T.
    Vermeire, Severine
    Louis, Edouard
    Robinson, Anne M.
    Lomax, Kathleen G.
    Pollack, Paul F.
    Paulson, Susan K.
    INFLAMMATORY BOWEL DISEASES, 2013, 19 (06) : 1112 - 1122
  • [32] Safety of Adalimumab in Global Clinical Trials of Patients with Crohn's Disease
    Colombel, Jean-Frederic
    Panaccione, Remo
    Sandborn, William
    Rutgeerts, Paul
    Hanauer, Stephen
    Reinisch, Walter
    Robinson, Anne
    Lau, Winnie
    Cardoso, Alexandra
    Pollack, Paul
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2010, 105 : S413 - S414
  • [33] QUALITY OF LIFE IN PATIENTS WITH CROHN'S DISEASE UNDER TREATMENT WITH ADALIMUMAB
    Sanjurjo Lucia, Fuster
    Laya Beatriz, Salazar
    Penin Isaura, Rodriguez
    Sandomingo Laura, Lopez
    Urbistondo Gema, Dominguez
    Barreira Rebeca, Iglesias
    ATENCION FARMACEUTICA, 2010, 12 (06): : 375 - 378
  • [34] Pharmacokinetics of Adalimumab in Pediatric Patients With Moderate to Severe Crohn's Disease
    Eckert, Doerthe
    Mensing, Sven
    Sharma, Shringi
    Thakkar, Roopal
    Robinson, Anne
    Hyams, Jeffrey S.
    Rosh, Joel R.
    Ruemmele, Frank
    Awni, Walid M.
    GASTROENTEROLOGY, 2013, 144 (05) : S228 - S228
  • [35] Is there a beneficial effect of adding azathioprine to adalimumab in Crohn's disease patients?
    Lowenberg, Mark
    ANNALS OF TRANSLATIONAL MEDICINE, 2018, 6 (13)
  • [36] Adalimumab for Cutaneous Metastatic Crohn's Disease
    Cury, Didia Bismara
    Moss, Alan C.
    Elias, Geraldo
    Nakao, Alexandre
    INFLAMMATORY BOWEL DISEASES, 2010, 16 (05) : 723 - 724
  • [37] Adalimumab: the efficacy and safety in Crohn's disease
    Foster, R.
    Ambikaipaker, V.
    Radvan, G.
    Lawrence, O.
    Daley, A.
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2010, 25 : A87 - A87
  • [38] Adalimumab for Crohn's disease after an abscess
    不详
    ZEITSCHRIFT FUR GASTROENTEROLOGIE, 2024, 62 (04):
  • [39] Adalimumab for maintenance of remission in Crohn's disease
    Townsend, Cassandra M.
    Nguyen, Tran M.
    Cepek, Jeremy
    Abbass, Mohamad
    Parker, Claire E.
    MacDonald, John K.
    Khanna, Reena
    Jairath, Vipul
    Feagan, Brian G.
    COCHRANE DATABASE OF SYSTEMATIC REVIEWS, 2020, (05):
  • [40] Ustekinumab vs adalimumab for Crohn's disease
    Baker, Holly
    LANCET GASTROENTEROLOGY & HEPATOLOGY, 2022, 7 (09): : 793 - 793
12345